Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation.

Holliday MJ, Witt A, Rodríguez Gama A, Walters BT, Arthur CP, Halfmann R, Rohou A, Dueber EC, Fairbrother WJ.

Nat Commun. 2019 Jul 11;10(1):3070. doi: 10.1038/s41467-019-10953-z.

2.

Cyclodextrin Reduces Intravenous Toxicity of a Model Compound.

Mantik P, Xie M, Wong H, La H, Steigerwalt RW, Devanaboyina U, Ganem G, Shih D, Flygare JA, Fairbrother WJ, Chakravarty P, Russell D, Fernandez GE, Narang AS.

J Pharm Sci. 2019 Jun;108(6):1934-1943. doi: 10.1016/j.xphs.2019.01.004. Epub 2019 Jan 11.

PMID:
30639736
3.

Picomolar zinc binding modulates formation of Bcl10-nucleating assemblies of the caspase recruitment domain (CARD) of CARD9.

Holliday MJ, Ferrao R, de Leon Boenig G, Estevez A, Helgason E, Rohou A, Dueber EC, Fairbrother WJ.

J Biol Chem. 2018 Oct 26;293(43):16803-16817. doi: 10.1074/jbc.RA118.004821. Epub 2018 Sep 11.

PMID:
30206119
4.

Publisher Correction: A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells.

Nile AH, de Sousa E Melo F, Mukund S, Piskol R, Hansen S, Zhou L, Zhang Y, Fu Y, Gogol EB, Kömüves LG, Modrusan Z, Angers S, Franke Y, Koth C, Fairbrother WJ, Wang W, de Sauvage FJ, Hannoush RN.

Nat Chem Biol. 2018 Sep;14(9):902. doi: 10.1038/s41589-018-0069-5.

PMID:
29728602
5.

A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells.

Nile AH, de Sousa E Melo F, Mukund S, Piskol R, Hansen S, Zhou L, Zhang Y, Fu Y, Gogol EB, Kömüves LG, Modrusan Z, Angers S, Franke Y, Koth C, Fairbrother WJ, Wang W, de Sauvage FJ, Hannoush RN.

Nat Chem Biol. 2018 Jun;14(6):582-590. doi: 10.1038/s41589-018-0035-2. Epub 2018 Apr 9. Erratum in: Nat Chem Biol. 2018 May 4;:.

PMID:
29632413
6.

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.

Goncharov T, Hedayati S, Mulvihill MM, Izrael-Tomasevic A, Zobel K, Jeet S, Fedorova AV, Eidenschenk C, deVoss J, Yu K, Shaw AS, Kirkpatrick DS, Fairbrother WJ, Deshayes K, Vucic D.

Mol Cell. 2018 Feb 15;69(4):551-565.e7. doi: 10.1016/j.molcel.2018.01.016.

7.

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A.

Cancer Discov. 2017 Dec;7(12):1376-1393. doi: 10.1158/2159-8290.CD-17-0797. Epub 2017 Nov 16. Review.

8.

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.

Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, Salles G, Sujobert P.

Am J Hematol. 2017 Jun;92(6):515-519. doi: 10.1002/ajh.24701. Epub 2017 Mar 24.

9.

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.

Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ.

Nat Rev Drug Discov. 2017 Apr;16(4):273-284. doi: 10.1038/nrd.2016.253. Epub 2017 Feb 17. Review.

PMID:
28209992
10.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR.

Clin Cancer Res. 2016 Sep 15;22(18):4567-73. doi: 10.1158/1078-0432.CCR-16-0308. Epub 2016 Apr 13.

11.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

12.

Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.

Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, Ramamoorthi N, Kategaya L, Newman RJ, Horikawa K, Dugger D, Sandoval W, Mukund S, Zindal A, Martin F, Quan C, Tom J, Fairbrother WJ, Townsend M, Warming S, DeVoss J, Liu J, Dueber E, Caplazi P, Lee WP, Goodnow CC, Balazs M, Yu K, Kolumam G, Dixit VM.

Nature. 2016 Apr 21;532(7599):402. doi: 10.1038/nature16541. Epub 2016 Jan 13. No abstract available.

PMID:
26760210
13.

Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.

Noland CL, Gierke S, Schnier PD, Murray J, Sandoval WN, Sagolla M, Dey A, Hannoush RN, Fairbrother WJ, Cunningham CN.

Structure. 2016 Jan 5;24(1):179-186. doi: 10.1016/j.str.2015.11.005. Epub 2015 Dec 24.

14.

Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.

Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, Ramamoorthi N, Kategaya L, Newman RJ, Horikawa K, Dugger D, Sandoval W, Mukund S, Zindal A, Martin F, Quan C, Tom J, Fairbrother WJ, Townsend M, Warming S, DeVoss J, Liu J, Dueber E, Caplazi P, Lee WP, Goodnow CC, Balazs M, Yu K, Kolumam G, Dixit VM.

Nature. 2015 Dec 17;528(7582):370-5. doi: 10.1038/nature16165. Epub 2015 Dec 9. Erratum in: Nature. 2016 Apr 21;532(7599):402.

PMID:
26649818
15.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.

PMID:
25787766
16.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L, Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam MJ, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore SW, Souers AJ.

Cell Death Dis. 2015 Jan 15;6:e1590. doi: 10.1038/cddis.2014.561.

17.

Internal motions prime cIAP1 for rapid activation.

Phillips AH, Schoeffler AJ, Matsui T, Weiss TM, Blankenship JW, Zobel K, Giannetti AM, Dueber EC, Fairbrother WJ.

Nat Struct Mol Biol. 2014 Dec;21(12):1068-74. doi: 10.1038/nsmb.2916. Epub 2014 Nov 10.

PMID:
25383668
18.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ.

ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. doi: 10.1021/ml5001867. eCollection 2014 Oct 9.

19.

Designer proteins to trigger cell death.

Fairbrother WJ, Ashkenazi A.

Cell. 2014 Jun 19;157(7):1506-8. doi: 10.1016/j.cell.2014.06.010.

20.

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Koehler MF, Bergeron P, Choo EF, Lau K, Ndubaku C, Dudley D, Gibbons P, Sleebs BE, Rye CS, Nikolakopoulos G, Bui C, Kulasegaram S, Kersten WJ, Smith BJ, Czabotar PE, Colman PM, Huang DC, Baell JB, Watson KG, Hasvold L, Tao ZF, Wang L, Souers AJ, Elmore SW, Flygare JA, Fairbrother WJ, Lessene G.

ACS Med Chem Lett. 2014 Mar 21;5(6):662-7. doi: 10.1021/ml500030p. eCollection 2014 Jun 12.

21.

Further insights into the effects of pre-organizing the BimBH3 helix.

Okamoto T, Segal D, Zobel K, Fedorova A, Yang H, Fairbrother WJ, Huang DC, Smith BJ, Deshayes K, Czabotar PE.

ACS Chem Biol. 2014 Mar 21;9(3):838-9. doi: 10.1021/cb400638p. Epub 2014 Feb 18. No abstract available.

PMID:
24547872
22.

Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.

Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE 3rd, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, Fairbrother WJ.

Drug Metab Dispos. 2013 Dec;41(12):2104-13. doi: 10.1124/dmd.113.053926. Epub 2013 Sep 16.

PMID:
24041744
23.

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling.

Phillips AH, Zhang Y, Cunningham CN, Zhou L, Forrest WF, Liu PS, Steffek M, Lee J, Tam C, Helgason E, Murray JM, Kirkpatrick DS, Fairbrother WJ, Corn JE.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11379-84. doi: 10.1073/pnas.1302407110. Epub 2013 Jun 25.

24.

Structure-guided design of a selective BCL-X(L) inhibitor.

Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, Colman PM, Deshayes K, Fairbrother WJ, Flygare JA, Gibbons P, Kersten WJ, Kulasegaram S, Moss RM, Parisot JP, Smith BJ, Street IP, Yang H, Huang DC, Watson KG.

Nat Chem Biol. 2013 Jun;9(6):390-7. doi: 10.1038/nchembio.1246. Epub 2013 Apr 21.

PMID:
23603658
25.

Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.

Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, Williams K, Savy PP, Yue P, Sampath D, Settleman J, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2013 Jun;12(6):853-64. doi: 10.1158/1535-7163.MCT-12-0949. Epub 2013 Mar 8.

26.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW.

Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.

PMID:
23291630
27.

Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity.

Okamoto T, Zobel K, Fedorova A, Quan C, Yang H, Fairbrother WJ, Huang DC, Smith BJ, Deshayes K, Czabotar PE.

ACS Chem Biol. 2013 Feb 15;8(2):297-302. doi: 10.1021/cb3005403. Epub 2012 Dec 10.

PMID:
23151250
28.

Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.

Erickson RI, Tarrant J, Cain G, Lewin-Koh SC, Dybdal N, Wong H, Blackwood E, West K, Steigerwalt R, Mamounas M, Flygare JA, Amemiya K, Dambach D, Fairbrother WJ, Diaz D.

Toxicol Sci. 2013 Jan;131(1):247-58. doi: 10.1093/toxsci/kfs265. Epub 2012 Sep 5.

PMID:
22956632
29.

Characterization of ML-IAP protein stability and physiological role in vivo.

Varfolomeev E, Moradi E, Dynek JN, Zha J, Fedorova AV, Deshayes K, Fairbrother WJ, Newton K, Le Couter J, Vucic D.

Biochem J. 2012 Nov 1;447(3):427-36. doi: 10.1042/BJ20121103.

PMID:
22853455
30.

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis.

Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, Erickson R, Hop CE, LoRusso P, Eckhardt SG, Wagner A, Chan IT, Mamounas M, Flygare JA, Fairbrother WJ.

Toxicol Sci. 2012 Nov;130(1):205-13. doi: 10.1093/toxsci/kfs235. Epub 2012 Jul 28.

PMID:
22843607
31.

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ.

J Med Chem. 2012 May 10;55(9):4101-13. doi: 10.1021/jm300060k. Epub 2012 Mar 28.

32.

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2012 Apr;11(4):1026-35. doi: 10.1158/1535-7163.MCT-11-0693. Epub 2012 Feb 1.

33.

The structure of the extracellular domain of the jumping translocation breakpoint protein reveals a variation of the midkine fold.

Rousseau F, Pan B, Fairbrother WJ, Bazan JF, Lingel A.

J Mol Biol. 2012 Jan 6;415(1):22-8. doi: 10.1016/j.jmb.2011.10.048. Epub 2011 Nov 4.

PMID:
22079049
34.

Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination.

Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, Zobel K, Maurer B, Varfolomeev E, Wu P, Wallweber HJ, Hymowitz SG, Deshayes K, Vucic D, Fairbrother WJ.

Science. 2011 Oct 21;334(6054):376-80. doi: 10.1126/science.1207862.

35.

Murine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1.

Lobito AA, Ramani SR, Tom I, Bazan JF, Luis E, Fairbrother WJ, Ouyang W, Gonzalez LC.

J Biol Chem. 2011 May 27;286(21):18969-81. doi: 10.1074/jbc.M111.224626. Epub 2011 Mar 31.

36.

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJ, Leong KG, Dueber EC, Maecker H, Huang DC, Dixit VM.

Nature. 2011 Mar 3;471(7336):110-4. doi: 10.1038/nature09779. Erratum in: Nature. 2011 Jul 7;475(7354):122.

PMID:
21368834
37.

Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.

Sleebs BE, Czabotar PE, Fairbrother WJ, Fairlie WD, Flygare JA, Huang DC, Kersten WJ, Koehler MF, Lessene G, Lowes K, Parisot JP, Smith BJ, Smith ML, Souers AJ, Street IP, Yang H, Baell JB.

J Med Chem. 2011 Mar 24;54(6):1914-26. doi: 10.1021/jm101596e. Epub 2011 Mar 2.

PMID:
21366295
38.

Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.

Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD.

Clin Cancer Res. 2011 Mar 15;17(6):1394-404. doi: 10.1158/1078-0432.CCR-10-2353. Epub 2011 Jan 10.

39.

c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling.

Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, Helgason E, Fairbrother WJ, Deshayes K, Kirkpatrick DS, Vucic D.

EMBO J. 2010 Dec 15;29(24):4198-209. doi: 10.1038/emboj.2010.300. Epub 2010 Nov 26.

40.

Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.

Cohen F, Koehler MF, Bergeron P, Elliott LO, Flygare JA, Franklin MC, Gazzard L, Keteltas SF, Lau K, Ly CQ, Tsui V, Fairbrother WJ.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2229-33. doi: 10.1016/j.bmcl.2010.02.021. Epub 2010 Feb 8. Erratum in: Bioorg Med Chem Lett. 2012 Jan 1;22(1):753-4.

PMID:
20189383
41.

Small-molecule pan-IAP antagonists: a patent review.

Flygare JA, Fairbrother WJ.

Expert Opin Ther Pat. 2010 Feb;20(2):251-67. doi: 10.1517/13543770903567077. Review.

PMID:
20100005
42.

NMR assignments of the human cytokine interleukin-33.

Lingel A, Fairbrother WJ.

Biomol NMR Assign. 2009 Dec;3(2):223-5. doi: 10.1007/s12104-009-9180-6. Epub 2009 Jul 10.

PMID:
19888696
43.

X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists.

Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D.

J Biol Chem. 2009 Dec 11;284(50):34553-60. doi: 10.1074/jbc.M109.040139. Epub 2009 Oct 23.

44.

Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.

Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, Bazan JF, Fairbrother WJ.

Structure. 2009 Oct 14;17(10):1398-410. doi: 10.1016/j.str.2009.08.009.

45.

Phosphorylation of a borealin dimerization domain is required for proper chromosome segregation.

Bourhis E, Lingel A, Phung Q, Fairbrother WJ, Cochran AG.

Biochemistry. 2009 Jul 28;48(29):6783-93. doi: 10.1021/bi900530v.

PMID:
19530738
46.

Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists.

Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, Maurer B, Fedorova AV, Dynek JN, Koehler M, Hymowitz SG, Tsui V, Deshayes K, Fairbrother WJ, Flygare JA, Vucic D.

ACS Chem Biol. 2009 Jul 17;4(7):557-66. doi: 10.1021/cb900083m.

PMID:
19492850
47.

Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.

Cohen F, Alicke B, Elliott LO, Flygare JA, Goncharov T, Keteltas SF, Franklin MC, Frankovitz S, Stephan JP, Tsui V, Vucic D, Wong H, Fairbrother WJ.

J Med Chem. 2009 Mar 26;52(6):1723-30. doi: 10.1021/jm801450c.

PMID:
19228017
48.

Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1).

Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, Bazan JF, Fairbrother WJ, Deshayes K, Vucic D.

Biochem J. 2009 Jan 1;417(1):149-60. doi: 10.1042/BJ20081885.

PMID:
18939944
49.

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation.

Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D.

J Biol Chem. 2008 Sep 5;283(36):24295-9. doi: 10.1074/jbc.C800128200. Epub 2008 Jul 11.

50.

Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas.

Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D.

Cancer Res. 2008 May 1;68(9):3124-32. doi: 10.1158/0008-5472.CAN-07-6622.

Supplemental Content

Loading ...
Support Center